A Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 2 Study of ITM-058 in Patients with Postmenopausal Osteoporosis

Teijin Pharma Limited0 个研究点目标入组 164 人开始时间: 2013年12月17日最近更新: 2023年10月17日

适应症

试验速览

阶段: 2 期
状态: 已完成
发起方: Teijin Pharma Limited
入组人数: 164

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

Dependently on the dose of abaloparatide, lumbar spine (L1-L4 and L2-L4) BMD, femur (total) BMD, and osteogenesis marker levels increased as compared to the placebo. There were no clinically relevant findings or new safety concerns regarding safety.

研究设计

研究类型: Interventional

入排标准

年龄范围: >= 55age old 至 <= 85age old（—）
性别: Female

入选标准

•Patients with postmenopausal osteoporosis at high risk of fracture

排除标准

•Patients who may be affected by the secondary osteoporosis
•Patients who were treated with the drugs that may affect Calcium levels or bone metabolism
•Patients with a history of osteosarcoma

研究者

发起方

Teijin Pharma Limited

相似试验

已完成

3 期

ITM-058 Phase 3 studyOsteoporosis

JPRN-jRCT2080223520Teijin Pharma Limited213

已完成

3 期

Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and ResorptionOsteoporosis, PostmenopausalOsteoporosis VertebralOsteoporosis RiskOsteoporosis FractureOsteoporosis Localized to SpineOsteoporosis, Age-RelatedOsteoporosis SenileOsteoporosis of VertebraeOsteoporosis

NCT03710889Radius Health, Inc.23

已完成

3 期

Safety and Efficacy of Abaloparatide-SC in Men With Osteoporosis (ATOM)Osteoporosis, Age-RelatedOsteoporosis Localized to SpineAge Related OsteoporosisOsteoporosis SenileOsteoporosis of VertebraeOsteoporosis

NCT03512262Radius Health, Inc.228

已完成

2 期

Abaloparatide and Pelvic Fracture HealingFracture of Pelvis (Disorder)

NCT04249232Hospital for Special Surgery, New York48

已完成

4 期

Abaloparatide Before Total Knee ArthroplastyArthroplasties, Knee ReplacementOsteoporosis

NCT04167163University of Wisconsin, Madison58